Inhibrx Biosciences, Inc. (INBX) fair value analysis
Nasdaq · Updated 2026-10-19
INBX price how computed
Valuation status
No fair-value estimate yetINBX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for INBX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $89.83
- Sector
- Healthcare
- 12-month range
- $28.36–$141.84
- Market cap
- $1.32B
- From 52-week high
- -36.7%
- Shares outstanding
- 14.7M
- Rank in Healthcare by quality score
- #244 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Inhibrx Biosciences, Inc. is a biopharmaceutical company that discovers and develops monoclonal antibodies and other protein therapeutics for the treatment of oncology, immunology, and other diseases. The company operates in the United States and conducts research and development activities focused on advancing its pipeline of therapeutic candidates.
INBX currently ranks #244 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.32B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-8.88
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- -33.3%
- Shares outstanding
- 14.7M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 38 · neutral
- 50-day average
- $103.71
- 200-day average
- $91.54
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-13
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.4%)
2026-03 ▼ miss (-79.2%)
2025-12 ▼ miss (-29.4%)
2025-09 ▼ miss (-32.6%)
2025-06 ▲ beat (+28.8%)
2025-03 ▲ beat (+10.3%)
2024-12 ▼ miss (-114.6%)
2024-09 ▲ beat (+23.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 1 hold · 0 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $267
- Target vs last price
- +197.2%
What our data shows for INBX
- Shares are trading in the middle of their 12-month price range of $28.36–$141.84.
- The 14-day relative strength index sits at a neutral 38.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- INBX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the INBX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — INBX's relative strength index moved from oversold territory into neutral zone this week, indicating a shift in momentum dynamics for the Healthcare sector company. The stock's valuation assessment remains pending completion of full analysis. No other material changes to derived indicators were recorded during the period.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for INBX showed a shift in trend momentum this week, with the 50/200-day trend state moving from uptrend to mixed. The stock remains in the healthcare sector with a valuation verdict of awaiting full valuation. This change in trend state suggests reduced upside momentum compared to the prior week's assessment.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is INBX stock undervalued?
TickrTrends has no fair-value estimate for INBX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is INBX's TickrTrends verdict?
INBX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does INBX compare to other Healthcare stocks?
INBX ranks #244 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is INBX overbought or oversold?
INBX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does INBX report earnings next?
INBX's next earnings report is scheduled for 2026-11-13, per the published earnings calendar.
Does INBX usually beat earnings estimates?
Over its last 8 reported quarters INBX beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about INBX?
Of 4 analysts covering INBX, 3 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $267 (+197.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.